Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $11.00 at HC Wainwright
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price objective lowered by HC Wainwright from $12.00 to $11.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 160.05% from the stock’s previous close. HC Wainwright […]
More Stories
Speak Like a Pro in 2 Months with Lingoda’s Sprint Challenge – Join Now!
Language skills open many doors, be it for work, traveling, or personal growth. Confidence and speed in speaking come from...
Sowell Financial Services LLC Invests $629,000 in Arista Networks, Inc. (NYSE:ANET)
Sowell Financial Services LLC bought a new position in shares of Arista Networks, Inc. (NYSE:ANET – Free Report) in the...
Janney Montgomery Scott LLC Has $13.11 Million Holdings in Vanguard Small-Cap Growth ETF (NYSEARCA:VBK)
Janney Montgomery Scott LLC lessened its holdings in Vanguard Small-Cap Growth ETF (NYSEARCA:VBK – Free Report) by 10.6% during the...
Robertson Stephens Wealth Management LLC Decreases Stake in General Dynamics Corporation (NYSE:GD)
Robertson Stephens Wealth Management LLC trimmed its holdings in shares of General Dynamics Corporation (NYSE:GD – Free Report) by 9.0%...
Exchange Traded Concepts LLC Decreases Stock Position in CVS Health Corporation (NYSE:CVS)
Exchange Traded Concepts LLC cut its stake in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 17.0% in...
Robertson Stephens Wealth Management LLC Has $361,000 Stock Holdings in NIKE, Inc. (NYSE:NKE)
Robertson Stephens Wealth Management LLC decreased its stake in NIKE, Inc. (NYSE:NKE – Free Report) by 6.6% in the first...